According to filings with the U.S. Securities and Exchange Commission, Orbital Therapeutics is raising $270,000,000.00 in new funding. Sources indicate that as part of senior management Chairman, John Maraganore played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Orbital Therapeutics
Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines (excluding small interfering RNA) to treat human disease in ways that were not previously possible. The company is building a first-in-kind platform at the intersection of RNA technology, delivery methods, data science and automation to develop an expansive portfolio of medicines, initially focused in the areas of vaccines, immunomodulation, and protein replacement. Founded by experts in the fields of genetic medicine and RNA development and delivery, Orbital has an operational structure designed to harness the ingenuity of a deep and diverse team of scientists, drug developers and business leaders.

To learn more about Orbital Therapeutics, visit http://www.orbitaltx.com/

Contact:
John Maraganore, Chairman
252-227-7013

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.